• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » HRS 2012: Boston Scientific’s Watchman as effective as Warfarin

HRS 2012: Boston Scientific’s Watchman as effective as Warfarin

May 11, 2012 By Brad Perriello

HRS 2012

A medical device made by Boston Scientific (NYSE:BSX) designed to trap blood clots in the heart could be an important tool for preventing stroke in high-risk atrial fibrillation patients, researchers said today at the annual Heart Rhythm Society meeting in Boston.

A study comparing the Watchman left atrial appendage closure device with the anticoagulant drug Warfarin found the device to be more effective in preventing stroke in patients who can’t tolerate the drug. A previous trial showed that the Watchman device was the drug’s equal in preventing stroke in high-risk AF patients, but patients in that trial were treated with Warfarin for 6 weeks until LAA closure could be demonstrated.

Sign up to get our free newsletters delivered straight to your inbox

The most recent trial, using data from the ASA Plavix registry, showed that the device worked just as well even in the absence of Warfarin. The researchers enrolled 150 high-risk AF patients who couldn’t take Warfarin and successfully implanted the Watchman device in 141 (94%). After at least a year of follow-up care, there were 4 strokes, 1 embolism and 6 blood clots related to the device.

The study also showed that the Watchman device reduced the incidence of ischemic stroke by 75% in patients treated with just aspirin and cut the stroke rate by 64% in patients treated with aspirin and lifelong Clopidogrel, another blood clot preventer.

Asked if the Watchman device is a game-changer or just another tool in the electrophysiologist’s armamentarium, co-author Dr. Vivek Reddy of the Mount Sinai School of Medicine in New York told MassDevice.com that more studies are needed comparing the device with newer anticoagulants such as dabigatran.

"If the world only had Warfarin and the Watchman, I would say game-changing. As it is right now, I would say it’s an alternative. Right now we have drugs that are better than Warfarin and devices – I would say, that are better than Warfarin," Reddy told us this afternoon at the HRS conference. "So the question then is which of these do we use, or which in combination? You can’t say it’s game-changing unless you prove that 1 is better than the other. Basically, we don’t know which is better. That kind of a study, comparing the new drugs with appendage closure, those are future studies that need to be done."

Another question still to be answered is whether the 6-month post-implantation regimen of the anti-platelet drug Plavix is really necessary, he said.

"The bleeding rate from aspirin-and-Plavix is act quite high, it’s actually as high as Warfarin alone. So the question is, does this combination of these 2 things really add, from a safety perspective, or does it detract from a safety perspective," Reddy said. "The hypothesis behind Plavix is that it will help in the healing process with the device, but it’s not clear if Plavix does anything in terms of helping the healing process. It may be that all Plavix is doing is increasing our bleeding rates.

"The problem is still the older patients. Even with the new drugs, there’s still a risk for bleeding," he told us. "Fundamentally, the question is going to be, does it make sense to do local therapy with appendage closure as opposed to systemic therapy with a blood thinner you have to take every day. The cost may favor the Watchman device, because it’s a 1-time procedure. These are questions that are being raised, but we dont have answers yet."

"Watchman implantation without a Warfarin transition is safe and effective in AF patients with contraindications to even short-term oral anticoagulation," the researchers wrote. "The first formal results from the largest study of LAA closure in patients contraindicated to Warfarin demonstrate the Watchman may be an important alternative for high risk AF patients with limited options for stroke prevention."

"Watchman is the most studied LAA closure device with more than 2,000 patients enrolled in prospective studies and nearly 4,000 patient-years of follow up," BSX chief medical officer Dr. Keith Dawkins said in prepared remarks. "This novel device has been well received in more than 30 countries where it offers a safe and effective alternative to long-term treatment with oral anticoagulants."

"Findings from the ASAP Study are promising in that closure of the LAA with the Watchman Device produced a significant reduction in the expected ischemic stroke rate for this patient population," added lead investigator Dr. Vivek Reddy. "These results are very impressive and show potential for an effective device-based solution for higher-risk patients with limited pharmacologic options to reduce their risk of stroke."

Boston Scientific acquired the Watchman technology in a $100 million buyout of Plymouth, Minn.-based Atritech last year. The value of the deal could spike to $375 million if Watchman meets certain financial and regulatory milestones. In November 2010, Atritech began enrolling patients in the Prevail clinical study, aiming to win a nod from the Food & Drug Administration for the device. It would be the first LAA closure device to reach what could be a $1 billion U.S. market in the next few years, Leerink Swan analyst Rick Wise wrote at the time.

"Although Atritech is a small deal for BSX, we believe this is an interesting take on a potentially compelling new market. That market’s potential now is essentially being validated by two large cardiology players (BSX and [St. Jude Medical (NYSE:STJ)]). STJ’s recent AGA purchase – whose new product pipeline also includes LAA closure technology – along with BSX’s announcement today could suggest that the the LAA closure opportunity is indeed real," according to Wise.

"In structural heart, we continue to expand the commercial presence of our Watchman Device outside the United States while in the United States, we remain on track to complete enrollment in the Prevail trial and submit our PMA by the end of the year," interim CEO Hank Kucheman told analysts last month. "This would set us up for expected FDA approval and launch in the second half of 2013, which we expect will allow us to be the first to market in the United States with this novel technology for a considerable period of time."

The Atritech deal is part of Boston Scientific’s efforts to broaden its portfolio of less-invasive cardiovascular devices.

"The Atritech acquisition significantly strengthens our product offerings in the fast-growing areas of structural heart therapy and atrial fibrillation, which represent two of our Priority Growth Initiatives," CEO Ray Elliott said when the deal closed last year. "Left atrial appendage closure represents a significant growth opportunity for Boston Scientific, and Atritech’s Watchman device is the first such product for atrial fibrillation patients at high risk for stroke."

In February 2011, Boston Scientific added two products for treating peripheral chronic total occlusions to its portfolio of cardiovascular devices.

Filed Under: Cardiac Implants, News Well Tagged With: Boston Scientific, Clinical Trials, HRS 2012

In case you missed it

  • Calyxo raises $32.7M for kidney stone treatment
  • Getinge anesthesia systems recall is Class I
  • RefleXion closes $125M debt facility
  • Senseonics announces equity grants to employees
  • New data backs Aerin’s RhinAer for treating chronic rhinitis
  • Enovis completes Insight Medical acquisition
  • Orchestra BioMed to go public, partner with Medtronic on cardiac neuromodulation therapy
  • Memic Innovative Surgery is now Momentis Surgical
  • Lyra Therapeutics appoints new chief medical officer
  • Masimo’s SafetyNet monitoring reduced length of COVID-19 hospital stays, study says
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
  • Teva appoints former Vertex exec as new head of R&D, CMO
  • Enovis partners with Kelvi on hot and cold therapies
  • West Pharmaceutical Services debuts new needle syringe system
  • Titan Medical names Cary G. Vance as new president, CEO
  • Acutus completes first closing in left-heart access portfolio sale to Medtronic
  • FDA clears Intuitive, Siemens Healthineers imaging integration for robotic bronchoscopy

RSS From Medical Design & Outsourcing

  • FDA can’t explain drop in device recalls, but experts point to COVID disruptions
    The FDA acknowledged interruptions with notifications from recalling firms during the pandemic, while regulatory experts point to fewer inspections and fewer procedures. FDA medical device product recalls dropped last year to their lowest level since 2013, according to a Medical Design & Outsourcing analysis of recall data from the regulatory agency. Medtech regulatory experts said the COVID-19… […]
  • DeviceTalks Boston 2022: Here’s what you missed on the show floor
    At DeviceTalks Boston 2022, there was a wealth of expertise to be had from exhibitors including Viant, ICS, PSN Labs, Propel and more. From stories of overcoming challenges during the COVID-19 pandemic to medical device materials pitfalls to avoid, MassDevice and MDO executive editor Chris Newmarker hit the DeviceTalks Boston show floor to discover insights. […]
  • Supply Chain EVP Greg Smith sees fewer suppliers in Medtronic’s future
    All eyes are on Medtronic’s global operations and supply chain leader as he works to modernize its operations and scrutinize suppliers. EVP of Global Operations and Supply Chain Greg Smith anticipates fewer suppliers in Medtronic’s future, he said in an interview this week. Smith spoke with DeviceTalks Editorial Director Tom Salemi in his first published… […]
  • CeQur is launching a discreet, convenient ‘wearable insulin pen’
    CeQur designed its Simplicity device to make insulin delivery as seamless as possible for people with diabetes. When it comes to managing diabetes, CeQur wants to make insulin therapy as convenient as possible. For those who prefer to manage their own insulin delivery, the Simplicity device might just do exactly that. Simplicity, a wearable, disposable… […]
  • Meddux opens new facility in Colorado
    Engineering, design, development and manufacturing company Meddux announced that it opened a new facility in Boulder, Colorado. The new, 22,000-square-foot facility doubles the overall square footage from its previous location in Colorado. According to a news release, it helps the company to quadruple its product development area and double its manufacturing footprint. Meddux’s new facility… […]
  • Reducing the Overall Cost of Validation
    By PTI Engineered Plastics Reliable medical devices and equipment are essential for researchers and doctors to accurately diagnose and treat a wide range of diseases. That is why there is such stringent oversight from the FDA to ensure these products meet the necessary requirements and specifications. To ensure compliance with regulators, manufacturers follow installation qualification… […]
  • BBS Automation has a deal to buy medtech supplier Kahle Automation
    BBS Automation said it plans to purchase high-speed automation supplier Kahle Automation to expand its medtech and life sciences business. Kahle will operate as Kahle – a BBS Company, according to a news release from Munich, Germany-based BBS and Lombardy, Italy-based Kahle. The deal is subject to regulatory approval. Terms were not disclosed. Kahle’s co-owners —… […]
  • How safe is health information after the overturning of Roe?
    The U.S. Department of Health and Human Services today issued guidance meant to better protect women’s health information as state abortion bans kick in after the U.S. Supreme Court’s overturning of Roe v. Wade. Despite the HHS actions, women may still wonder whether their health information is entirely safe going forward — a potential challenge… […]
  • Dexcom focuses on early diabetes diagnosis as COVID links emerge
    New evidence is showing that COVID-19 may increase a person’s risk of diabetes, but it could be years until we know for sure. In the meantime, Dexcom (Nasdaq:DXCM) is getting ready, VP of Global Clinical Initiatives Tomas Walker said. Walker recently spoke with Medical Design & Outsourcing to discuss the San Diego-based diabetes device developer’s… […]
  • Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
    Blackrock Neurotech and the University of Pittsburgh’s Rehab Neural Engineering Labs (Pitt RNEL) are working together on the first portable brain-computer interface (BCI) to allow patients to participate in research trials from home. A Blackrock representative said it’s the final step as the company prepares to launch its first commercial product early next year. Salt… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS